{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T11:18:35Z","timestamp":1768475915208,"version":"3.49.0"},"reference-count":38,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000659","name":"Research Trainees Coordinating Centre","doi-asserted-by":"publisher","award":["NIHR 302841"],"award-info":[{"award-number":["NIHR 302841"]}],"id":[{"id":"10.13039\/501100000659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000691","name":"Academy of Medical Sciences","doi-asserted-by":"publisher","award":["SG023\\1048"],"award-info":[{"award-number":["SG023\\1048"]}],"id":[{"id":"10.13039\/501100000691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/V006118\/1"],"award-info":[{"award-number":["MR\/V006118\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2022,11,6]]},"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1183\/13993003.02091-2022","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T16:12:42Z","timestamp":1668701562000},"page":"2202091","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["GM-CSF targeting in COVID-19: an approach based on fragile foundations"],"prefix":"10.1183","volume":"61","author":[{"given":"Katharina","family":"Kohler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3211-3216","authenticated-orcid":false,"given":"Andrew","family":"Conway Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"key":"2024102103093062000_61.2.2202091.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.06.067"},{"key":"2024102103093062000_61.2.2202091.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.08.016"},{"key":"2024102103093062000_61.2.2202091.3","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4585"},{"key":"2024102103093062000_61.2.2202091.4","doi-asserted-by":"crossref","unstructured":"Guo SA , Bowyer GS , Ferdinand JR , et al. Obesity is associated with attenuated tissue immunity in COVID-19. Am J Respir Crit Care Med 2022; in press [https:\/\/doi.org\/10.1164\/rccm.202204-0751OC]. doi:10.1164\/rccm.202204-0751oc","DOI":"10.1164\/rccm.202204-0751OC"},{"key":"2024102103093062000_61.2.2202091.5","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1007\/s00134-021-06509-9","article-title":"Post-mortem dissection of COVID-19: a pathogenic role for macrophages?","volume":"47","author":"Velu","year":"2021","journal-title":"Intensive Care Med"},{"key":"2024102103093062000_61.2.2202091.6","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s10067-020-05569-4","article-title":"Haemophagocytic syndrome and COVID-19","volume":"40","author":"Retamozo","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2024102103093062000_61.2.2202091.7","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1007\/s00284-021-02657-9","article-title":"Molecular insights into the crosstalk between immune inflammation nexus and SARS-CoV-2 virus","volume":"78","author":"Bose","year":"2021","journal-title":"Curr Microbiol"},{"key":"2024102103093062000_61.2.2202091.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17023"},{"key":"2024102103093062000_61.2.2202091.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100433"},{"key":"2024102103093062000_61.2.2202091.10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijid.2022.01.040","article-title":"Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19","volume":"117","author":"San-Juan","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2024102103093062000_61.2.2202091.11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S2213-2600(21)00460-4","article-title":"Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial","volume":"10","author":"Fisher","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2024102103093062000_61.2.2202091.12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-2600(20)30556-7","article-title":"Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial","volume":"9","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024102103093062000_61.2.2202091.13","first-page":"A5768","article-title":"SPRINTER: a randomized, double-blind, placebo-controlled, phase 3 trial to determine the efficacy and safety of inhaled interferon beta-1a (SNG001) for the treatment of patients hospitalized due to COVID-19 (NCT04732949)","volume":"205","author":"Monk","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102103093062000_61.2.2202091.14","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2205017"},{"key":"2024102103093062000_61.2.2202091.15","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-211323"},{"key":"2024102103093062000_61.2.2202091.16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200903-0363OC"},{"key":"2024102103093062000_61.2.2202091.17","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200001000-00001"},{"key":"2024102103093062000_61.2.2202091.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-018-0164-2"},{"key":"2024102103093062000_61.2.2202091.19","doi-asserted-by":"publisher","DOI":"10.1093\/nsr\/nwaa041"},{"key":"2024102103093062000_61.2.2202091.20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41577-020-0357-7","article-title":"GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches","volume":"20","author":"Lang","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2024102103093062000_61.2.2202091.21","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2006.0170"},{"key":"2024102103093062000_61.2.2202091.22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cyto.2004.03.019","article-title":"Orally administered IL-6 induces elevated intestinal GM-CSF gene expression and splenic CFU-GM","volume":"27","author":"Rollwagen","year":"2004","journal-title":"Cytokine"},{"key":"2024102103093062000_61.2.2202091.23","first-page":"L372","article-title":"Glucocorticoid regulation of GM-CSF: evidence for transcriptional mechanisms in airway epithelial cells","volume":"275","author":"Adkins","year":"1998","journal-title":"Am J Physiol"},{"key":"2024102103093062000_61.2.2202091.24","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S2213-2600(20)30267-8","article-title":"Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities","volume":"8","author":"Mehta","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024102103093062000_61.2.2202091.25","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04451-7"},{"key":"2024102103093062000_61.2.2202091.26","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2665-9913(21)00070-9","article-title":"Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial","volume":"3","author":"Cremer","year":"2021","journal-title":"Lancet Rheum"},{"key":"2024102103093062000_61.2.2202091.27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S2213-2600(21)00494-X","article-title":"Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial","volume":"10","author":"Temesgen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024102103093062000_61.2.2202091.28","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1164\/rccm.202108-1859OC","article-title":"Anti-granulocyte-macrophage colony-stimulating factor monoclonal antibody gimsilumab for COVID-19 pneumonia: a randomized, double-blind, placebo-controlled trial","volume":"205","author":"Criner","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102103093062000_61.2.2202091.29","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01870-2021"},{"key":"2024102103093062000_61.2.2202091.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3339"},{"key":"2024102103093062000_61.2.2202091.31","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s43587-021-00114-7","article-title":"SARS-CoV-2, COVID-19 and the ageing immune system","volume":"1","author":"Bartleson","year":"2021","journal-title":"Nat Aging"},{"key":"2024102103093062000_61.2.2202091.32","doi-asserted-by":"crossref","unstructured":"Temesgen Z , Kelley CF , Cerasoli F , et al. C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 \u201cLIVE-AIR\u201d trial. Thorax 2022; in press [https:\/\/doi.org\/10.1136\/thoraxjnl-2022-218744]. doi:10.1136\/thoraxjnl-2022-218744","DOI":"10.1136\/thoraxjnl-2022-218744"},{"key":"2024102103093062000_61.2.2202091.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.10.019"},{"key":"2024102103093062000_61.2.2202091.34","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1002\/sim.8689","article-title":"Dismantling the fragility index: a demonstration of statistical reasoning","volume":"39","author":"Potter","year":"2020","journal-title":"Stat Med"},{"key":"2024102103093062000_61.2.2202091.35","doi-asserted-by":"crossref","first-page":"e222973","DOI":"10.1001\/jamanetworkopen.2022.2973","article-title":"The fragility of statistically significant results in randomized clinical trials for COVID-19","volume":"5","author":"Itaya","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024102103093062000_61.2.2202091.36","unstructured":"Kiniksa Pharmaceuticals . Kiniksa Announces Results from Phase 3 Trial of Mavrilimumab in COVID-19-Related ARDS. 2021. Date last accessed: 27 November 2022. https:\/\/investors.kiniksa.com\/news-releases\/news-release-details\/kiniksa-announces-results-phase-3-trial-mavrilimumab-covid-19"},{"key":"2024102103093062000_61.2.2202091.37","unstructured":"Humanigen Inc. Humanigen Receives Preliminary Topline Data From NIH\/NIAID Study of Lenzilumab in ACTIV-5\/BET-B. 2022. Date last accessed: 27 November 2022. https:\/\/ir.humanigen.com\/English\/news\/news-details\/2022\/Humanigen-Receives-Preliminary-Topline-Data-From-NIHNIAID-Study-of-Lenzilumab-in-ACTIV-5BET-B\/default.aspx"},{"key":"2024102103093062000_61.2.2202091.38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12874-021-01324-8","article-title":"Delays in reporting and publishing trial results during pandemics: cross sectional analysis of 2009 H1N1, 2014 Ebola, and 2016 Zika clinical trials","volume":"21","author":"Jones","year":"2021","journal-title":"BMC Med Res Methodol"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.02091-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:06:40Z","timestamp":1740377200000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.02091-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,2]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1183\/13993003.02091-2022"],"URL":"https:\/\/doi.org\/10.1183\/13993003.02091-2022","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]}}}